Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. (600671) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd.

Why is Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.37%

Poor long term growth as Net Sales has grown by an annual rate of 0.10% and Operating profit at 33.77% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

The company has declared Positive results for the last 3 consecutive quarters

NET SALES(HY) At CNY 143.44 MM has Grown at 127.88%
NET PROFIT(HY) Higher at CNY 24.49 MM
ROCE(HY) Highest at 70.83%

With ROE of 76.01%, it has a fair valuation with a 36.15 Price to Book Value

Over the past year, while the stock has generated a return of 83.21%, its profits have risen by 237.8% ; the PEG ratio of the company is 0.2

Market Beating Performance

The stock has generated a return of 83.21% in the last 1 year, much higher than market (China Shanghai Composite) returns of 14.77%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd.

83.21%

2.86

40.38%

China Shanghai Composite

14.77%

1.01

14.58%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.10%

EBIT Growth (5y)

33.77%

EBIT to Interest (avg)

-3.09

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.87

Sales to Capital Employed (avg)

1.21

Tax Ratio

20.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.37%

ROE (avg)

12.29%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

36.15

EV to EBIT

41.86

EV to EBITDA

27.96

EV to Capital Employed

12.89

EV to Sales

9.22

PEG Ratio

0.20

Dividend Yield

ROCE (Latest)

30.80%

ROE (Latest)

76.01%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company

NET SALES(HY)

At CNY 143.44 MM has Grown at 127.88%

NET PROFIT(HY)

Higher at CNY 24.49 MM

ROCE(HY)

Highest at 70.83%

INVENTORY TURNOVER RATIO(HY)

Highest at 2.68%

RAW MATERIAL COST(Y)

Fallen by -100.82% (YoY

-5What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY -42.75 MM

INTEREST(Q)

At CNY 1.32 MM has Grown at 404.88%

PRE-TAX PROFIT(Q)

At CNY 4.57 MM has Fallen at -38.35%

Here's what is working for Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd.

Net Sales

At CNY 143.44 MM has Grown at 127.88%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CNY MM)

Net Profit

At CNY 24.49 MM has Grown at 219.25%

Year on Year (YoY)

MOJO Watch

Net Profit trend is very positive

Net Profit (CNY MM)

Net Profit

Higher at CNY 24.49 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Inventory Turnover Ratio

Highest at 2.68% and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -100.82% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hangzhou Tian-Mu-Shan Pharmaceutical Enterprise Co., Ltd.

Interest

At CNY 1.32 MM has Grown at 404.88%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Cash Flow

Lowest at CNY -42.75 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Pre-Tax Profit

At CNY 4.57 MM has Fallen at -38.35%

over average net sales of the previous four periods of CNY 7.41 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)